Welcome

Sign out Have a question? We're here to help

Sign out

Phunware, Inc. - Common Stock (PHUN)

$1.25 0.04 (3.10%)

12:27 EDT PHUN Stock Quote Delayed 30 Minutes

Volume:

Previous Close $1.29

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 923,048

Day's Range 1.23 - 1.28

52-Week Range 0.54 - 5.50

Dividend & Yield N/A (N/A)

PHUN Stock Predictions, Articles, and Phunware, Inc. - Common Stock News

From the Web

Best & Worst Performing Mid Cap Stocks for May 29, 2020

From StockNews.com May 29, 2020

WSM – WSM leads the way today as the best performing mid cap stock, closing up 14.31%.

Friday’s Midday Movers: Dynavax (DVAX), Zynga (ZNGA), TG Therapeutics (TGTX), Harley-Davidson (HOG), Pan American Silver (PAAS)

From Analyst Ratings May 29, 2020

So far Friday, May 29, NASDAQ is up 0.12% and the S&P is down -1.33%. Here are this morning’s most active stocks: Dynavax (DVAX – Research Report), Zynga (ZNGA – Research Report), TG Therapeutics (TGTX – Research Report), Harley-Davidson (HOG – Research Report) and Pan American Silver (PAAS – Research Report). Dynavax is up 10.66%

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX) and Allogene Therapeutics (NASDAQ: ALLO)

From Analyst Ratings May 29, 2020

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Allogene Therapeutics (ALLO – Research Report) with bullish sentiments. TG Therapeutics (TGTX) H.C. Wainwright analyst Edward White maintained a Buy rating on TG Therapeutics today and set a price target

TG Therapeutics' ublituximab doublet therapy shows benefit in CLL (NASDAQ:TGTX)

From Seeking Alpha May 29, 2020

TG Therapeutics's (TGTX +0.2%) Phase 3 trial of ublituximab + ibrutinib combination demonstrated significant improvement in overall response rate (ORR) compared to ibrutinib monotherapy (93% v

TG Therapeutics reports Phase 3 results of ublituximab + ibrutinib combination in CLL patients (NASDAQ:TGTX)

From Seeking Alpha May 29, 2020

TG Therapeutics (TGTX +0.2%) announces the addition of ublituximab to ibrutinib significantly improves ORR compared to ibrutinib monotherapy (93% compared to 78%)Complete response/complete response wi

The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

From Benzinga May 27, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE:...

Navellier Ratings

Total Grade

Sell

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Welcome

Phunware, Inc. - Common Stock (PHUN)

Navellier Ratings

Total Grade

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Already a subscriber?

Welcome

Phunware, Inc. - Common Stock (PHUN)

PHUN Stock Predictions, Articles, and Phunware, Inc. - Common Stock News

Best & Worst Performing Mid Cap Stocks for May 29, 2020

Friday’s Midday Movers: Dynavax (DVAX), Zynga (ZNGA), TG Therapeutics (TGTX), Harley-Davidson (HOG), Pan American Silver (PAAS)

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX) and Allogene Therapeutics (NASDAQ: ALLO)

TG Therapeutics' ublituximab doublet therapy shows benefit in CLL (NASDAQ:TGTX)

TG Therapeutics reports Phase 3 results of ublituximab + ibrutinib combination in CLL patients (NASDAQ:TGTX)

The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Navellier Ratings

Total Grade

Subscriber Sign in